Centiva Capital’s Sage Therapeutics SAGE Stock Holding History

Centiva Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,000	Closed	-$1.48M	–	1557
2021 Q2	$1.48M	Buy	+26,000	New	+$1.84M	0.03%	419

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Centiva Capital's SAGE Position: Q3 2021 in Review

Centiva Capital sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 564 shares — an estimated $32K sold.

Centiva Capital first reported a position in SAGE in Q4 2019 and held it in 3 quarters. The position peaked at $283K in Q1 2020. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

Centiva Capital reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
Centiva Capital sold 564 Sage Therapeutics shares in Q3 2021, an estimated $32K.
Centiva Capital first reported a position in Sage Therapeutics in Q4 2019 and held it in 3 quarters.
Centiva Capital's Sage Therapeutics position peaked at $283K in Q1 2020.
226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Centiva Capital's 13F filing for Q3 2021, filed 15 Nov 2021.